Ensysce Biosciences, Inc.
- Last sale
- Nov 12, 2026 · +12.22%
- Market cap
- $7.63M
- 19.46M shares
- Filings
- 550
Q3 2026−2.8% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2025derived
—Q3 2026N/M FY25 yoy
Q3 2026+23.1% FY25 yoy
- $7.63M
- —
- 1.2×
- 0.3×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $5,066,650 | reported | |
| FY 2024 | 2024-12-31 | $5,210,031 | reported | |
| FY 2023 | 2023-12-31 | $2,230,520 | reported | |
| FY 2022 | 2022-12-31 | $2,523,383 | reported | |
| FY 2021 | 2021-12-31 | $3,531,199 | reported | |
| FY 2020 | 2020-12-31 | $3,931,209 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2020 | — | $184.78M | $184.78M | — | 6.22M sh | −73.9% | — |
| FY2019 | — | $11.58M | $11.58M | — | 23.88M sh | −4.5% | — |
Segments
Products
LineFY2025ShareChange
MPAR$5.07M100%+64.2%
TAAP/OUD———
Total$5.07M
Pharmaceutical preparations
Ensysce Biosciences, Inc. is the 188th largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
IMNMImmunome Inc.$6.9M23.2%3,060.0%$2.2BKYNBKyntra Bio, Inc.$6.4M78.3%2,848.6%$19.6MKRROKorro Bio, Inc.$6.4M181.5%1,834.5%$196.1MABEOAbeona Therapeutics Inc.$5.8M—1,223.1%$130.6MCNSYCerenome, Inc.$5.2M10.5%429.4%$5.7M
ENSCEnsysce Biosciences, Inc. (this company)$5.1M2.8%200.8%$7.6M
PRPHProPhase Labs, Inc.$4.3M35.8%339.3%$1.1MCPHIChina Pharma Holdings, Inc.$4.1M8.5%76.9%$24.1MCRVOCervoMed Inc.$4.0M58.9%673.1%$27.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Ensysce Biosciences, Inc. · CIK 1716947 · Engraved from SEC EDGAR